Longterm

• Treat Johnson’s October 2026 young-stroke relay as an attributed research relay with an exactly verified core figure and aged-up framing. “Strokes in young people used to be considered freak events… In stroke patients aged 18–35, those with 3+ major cardiovascular warning signs jumped by 50% in eight years. The culprits: high blood pressure, high cholesterol, obesity, and smoking.” traces to “Temporal Trends in Vascular Risk Factor Burden Among Young Adults With Ischemic Stroke — The Florida Stroke Registry,” Neurology, March 25, 2025 (10.1212/WNL.0000000000213447): 36,488 GWTG-Stroke ischemic-stroke patients 2014–2022, 3,363 aged 18–35, 3+ VRF polymorbidity 10.9%→16.4% (p=0.002) — a 50.4% relative jump in exactly eight years, with the post’s four named culprits all on the paper’s nine-factor list. Boundaries: hospitalized-patient share, not population risk; relative not absolute (5.5 percentage points); Florida hospital registry, not a population sample; “new study” is 19 months old and unnamed; “bodies of 60 yr olds” is gloss — risk-factor counts, not biological age; association, not demonstrated cause. Not evidence about any reader’s stroke risk, a screening recommendation, or medical advice.https://x.com/bryan_johnson/status/2115912558372626513
• Treat Blueprint as a repeatable feedback system whose rules can evolve as biomarkers, symptoms, or evidence change.concepts/blueprint-protocol.md
• Track the June 2026 sauna/HSP27 thread as a protocol-design case study: Johnson shifted the dose question from minutes in the sauna to measured core temperature and biomarker response.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
• Treat the July 2026 sauna checklist as Johnson’s attributed protocol guidance. Its 4–7-session frequency, heat-dose targets, fertility and microplastics claims, hydration advice, and environmental cautions are not a reader prescription or independent evidence of longevity benefit.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
• Track the June 2026 jet-lag follow-up as a self-reported caffeine + melatonin test using blood glucose as a body-clock readout, not as general travel medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md
• Treat the June 2026 Australian sun/skin-aging post as a skin-readout example inside the measurement loop, not as validated skincare advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
• Treat the June 2026 Immortals Rx expansion separately from foundational habits; the GLP-1, SGLT2, peptide, and NAD+ catalog is a commercial/protocol claim that requires clinician oversight.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
• Treat the July 2026 six-option GLP-1 catalog as an Immortals Rx commercial update. Johnson names branded and compounded listings, but the post does not establish formulation status, availability, prescribing criteria, or safety and efficacy for longevity use.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
• Treat Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence intervention claim. He identifies the cited work as preclinical and the human evidence as observational; his proposed extension from sildenafil to tadalafil is not evidence of efficacy or a reason to combine medicines.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
• Treat Johnson’s June 2026 “one international trip per quarter” rule as a biomarker-derived personal boundary, not as a reader travel guideline.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
• Treat the June 2026 inherited-cancer DNA + RNA panel as germline risk-stratification context, not a diagnosis, universal screening recommendation, or validation of Johnson’s early-surveillance statistics.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
• Treat the July 2026 AIG single-cell immune-receptor sequencing thread as Johnson’s diagnostic follow-through: a cellular/receptor-level measurement layer, not a validated therapy or reader test recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
• Treat the July 2026 low-ferritin / Monoferric follow-up as Johnson’s self-reported AIG case and false-negative philosophy, not a general iron-infusion recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
• Treat the July 2026 AIG cure roadmap and “Bryan in a dish” model as a proposed personal experiment; it is not an approved autoimmune-disease cure, validated ex-vivo screening protocol, or reader treatment pathway.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
• Treat the July 2026 Kate Tolo endometriosis workup as multi-modality diagnostic-triangulation context; it is not a reader diagnostic pathway, independent validation, or proof that endometriosis can now be cured.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
• Treat the October 2026 endometriosis organoid posts as an attributed method disclosure, not cure or therapy evidence. The stated approach — 30 mL of menstrual blood to build an organoid plus 30 mL for single-cell molecular characterization, to “model out her disease and can test potential therapies” — matches real published science: Turco et al. 2021 (Communications Biology, 10.1038/s42003-021-02194-y) derived endometrial organoids from menstrual flow with 87% success and transcriptomic identity to biopsy organoids, and Boretto et al. 2019 (Nature Cell Biology, 10.1038/s41556-019-0360-z) established patient-derived endometriosis organoids amenable to drug screening. But published menstrual-flow organoids model the eutopic endometrium, not surgically proven lesions; no lab, partner, cell line, characterization, therapy test, or outcome is published; and the volumes are self-reported. Not a collection protocol readers can follow or medical advice.https://x.com/bryan_johnson/status/2111861961394962672
• Read Johnson’s October 2026 longevity-home energy ledger — 52 kWh/day for the longevity stack and 93 kWh/day for the whole house, against an EIA average-US-household ~29 kWh/day — as an attributed infrastructure disclosure, not a health claim or efficiency standard. The arithmetic is internally consistent (device list sums to 52 kWh; 52 × 80 ≈ the posted 4,200 phone charges), but the figures are self-reported single-day readings, the solar self-consumption (64 − 33 = 31 kWh) does not cover the longevity demand, the “80 phone charges per kWh” rendering assumes a ~12.5 Wh battery, and the post implies nothing about whether any listed device affects longevity outcomes.https://x.com/bryan_johnson/status/2112320547828945248
• Treat the October 2026 rapamycin-retrospective post as an attributed N=1 deprescribing narrative with real literature behind it, not a drug decision readers can transfer. Johnson stopped rapamycin September 28, 2024 (per his own Blueprint essay) after ~5 years of weekly/biweekly/alternating dosing produced what he calls a “mixed story” — skin/soft-tissue infections, lipid abnormalities, glucose elevations, higher resting heart rate — and the peer-reviewed skepticism he now cites verifies in direction (Lancet Healthy Longevity systematic review: immune/cardiovascular/integumentary gains but no endocrine/muscular/neurological effects and adverse lipid/infection signals; Frontiers in Aging 2025 and Aging 2024 reviews citing unresolved human efficacy). None of this tells any other person to stop or start rapamycin; it is monitoring-grade evidence about uncertainty.https://x.com/bryan_johnson/status/2112642762353021020
• Read the October 2026 minoxidil Phase 3 comparison as competitive pharmacy marketing built on accurately quoted but non-comparable numbers. His 36.4 hairs/cm² (Veradermics VDPHL01 17 mg/day, n=536 placebo-controlled Phase 3) vs 35.9 hairs/cm² (Panchaprateep & Luengarun, 5 mg/day, n=30 open-label) juxtaposition is cross-trial, not head-to-head — different populations, doses, formulations, and measurement methods — and the post pivots the comparison into “available now at my Immortals Pharmacy,” while low-dose oral minoxidil is off-label prescribing territory requiring clinician oversight. Not evidence of drug equivalence or a hair-loss treatment recommendation.https://x.com/bryan_johnson/status/2112558564216868987
• Read Johnson’s October 2026 gray-market peptide warning as a verified consumer-safety relay, not a purchasing directive. Every checkable figure in the post matches the public record — TRM Labs’ October 6 blockchain analysis (150+ Chinese chemical vendors taking crypto, ~75% listing both peptides and fentanyl precursors, inflows $28.2M→$37.3M over 2023–2025, ~57% of identifiable value US-sourced), the WSJ’s ~200-tracked-firms/at-least-50-selling-peptides count, Anhui Rencheng’s June 2023 DOJ indictment with semaglutide and Melanotan II still listed as of September 2026, CBP’s master-carton seizures (~400 operations, 2,400+ seizures, 130,000+ vials October 2025–August 2026), and the two FAERS retatrutide death reports CBS reported October 13 — but TRM cannot separate peptide revenue from precursor revenue, the deaths are unverified-causation adverse-event reports, retatrutide is an unapproved investigational drug, and Johnson’s own Immortals Pharmacy sells peptides as the regulated alternative, an adjacency the post leaves implicit. Not an indictment of all peptide use, evidence regulated alternatives are risk-free, or medical advice.https://x.com/bryan_johnson/status/2113024548643996051
• Treat Johnson’s October 2026 N=1 self-critique as an attributed epistemic-boundary statement, not a repudiation of measurement. Endorsing an unnamed paper’s argument that his “biomarker numbers say less than people think” — aging is multi-scale and not directly measurable, “biomarkers are like the blind men touching the elephant,” N=1 shows “responsiveness but not durability; optimisation but not causality” — the position echoes the field’s own frameworks (no aging biomarker yet satisfies surrogate-endpoint validation; the TranslAGE database tests responsiveness, not outcome change). But the paper is unnamed and unlinked, the quoted critique is his transcription, and the proposed “simulation of aging system dynamics” is stated intent with no model, publication, or team disclosed. Not evidence biomarker tracking is useless, a disclosed research program, or medical advice.https://x.com/bryan_johnson/status/2112735624684093647
• Read the October 2026 GLP-1 gut self-experiment announcement as intent without a protocol. “T cells trigger severe gut lining damage / GLP agonists directly protect against intestinal destruction / I’m going to test this on myself” rests on real mouse science — Koehler et al., Cell Reports Medicine (10.1016/j.xcrm.2026.103115): T-cell activation induces intestinal GLP-1/GLP-2 secretion, Glp1r/Glp2r-knockout and gut-proglucagon-deficient mice suffer worse αCD3-induced enteropathy, and semaglutide and teduglutide each attenuate the damage — but it is acute work in young male mice with an antibody-induced injury model that a healthy human cannot reproduce, and the post names no drug, dose, design, or outcome. Not a sanctioned self-experiment, gut-health guidance, or medical advice.https://x.com/bryan_johnson/status/2112970692157395083
• Treat the October 2026 sauna equipment-and-rationale disclosure as attributed N=1 practice with a self-labeled hypothesis. The post itemizes “medical grade silicon,” ice on face, neck, scrotum, and CGM, 200°F (93°C), 20 min, 5×/week, and frames cooling face/neck as “a hypothesis of protecting from heat induced collagen breakdown” — his own hypothesis label, with directional cosmetic literature on heat and collagen but no test of the ice protocol itself; the silicon and ice-on-CGM details are personal practice, not a reader protocol.https://x.com/bryan_johnson/status/2112953793956737170
• Read Johnson’s October 2026 “Take earplugs everywhere” post as an attributed prevention directive, not a reader audiology recommendation. The medical direction verifies — hearing impairment is independently associated with accelerated whole-brain and right-temporal atrophy (Lin et al., NeuroImage 2014, BLSA n=126, 6.4-year follow-up: 8.4 vs 7.2 cm³/year), and the 2024 Lancet Commission ranks hearing loss among its 14 modifiable dementia risk factors (HR 1.37; hearing aids associated with 17% lower dementia risk; ACHIEVE RCT protective effect confined to its high-risk subgroup) — but the “environments routinely above 85 dBA” venue list overstates the measured record for restaurants and coffee shops (NYC SoundPrint survey of 2,376 venues averages 77–78 dBA, 25% above 81; subway platforms average 80.4 dBA with ~20% over 85), 85 dBA is an 8-hour workplace time-weighted limit rather than a momentary danger line, the post names no study, and no trial shows earplugs prevent cognitive decline. Prevention framing with verified context, not a hearing-protection prescription or medical advice.https://x.com/bryan_johnson/status/2113385315801199010
• Treat the October 2026 twice-yearly MRI readout as an attributed measurement disclosure, not evidence of youthful equivalence or a reader imaging recommendation. The self-reported figures — “subcutaneous and visceral fat - 20s equivalent,” “heart 100% score - 20s equivalent,” “hippocampal occupancy - 99th percentile,” scanner named as Prenuvo — summarize an unpublished private report with no reference cohort, normative dataset, or scoring method, and “radiologist report: my body is indistinguishable from an elite athlete” upgrades a quoted impression to a document. The screening-policy context the post omits: the American College of Radiology does not recommend total-body MRI screening for patients without symptoms, risk factors, or family history (April 17, 2023 statement), and the largest systematic review (J Magn Reson Imaging 2019, 10.1002/jmri.26736; 12 studies, 5,373 asymptomatic adults) found 32.1% pooled critical-or-indeterminate incidental findings with a 16.0% pooled false-positive proportion and no long-term verification of negative scans. Not evidence that twice-yearly whole-body MRI improves outcomes, a validated age-equivalence score, or medical advice.https://x.com/bryan_johnson/status/2115200763668631982
• Read Johnson’s July 2026 “removing harm” list as a subtraction-first behavior philosophy. Sleep consistency, movement, avoiding nicotine/alcohol, and reducing obvious hazards belong with foundations; the post does not quantify each item or resolve the safety and attribution questions around his intervention stack.raw/articles/bryan-johnson/x-twitter-daily-2026-07-11.md
• Treat the July 2026 Kate Tolo 90-day / 1,900-biomarker announcement as a projected N=1 program specification, not completed female-health evidence, a representative protocol, or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
• Treat Johnson’s RHR “Sovereignty Index” as within-person behavior-design framing. His reported 41 bpm average is not a universal target, and resting heart rate needs individual and clinical context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
• Treat the July 2026 ocular tear-panel post as an organ-specific measurement plan. Johnson reports a $1,800 specialty-lab panel across 15 biomarkers, but publishes no result, diagnosis, clinical utility, intervention, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
• Treat Immortals’ July 2026 disease-resolution infrastructure expansion as Johnson’s strategy and product positioning. The iPSC, organoid, deep-cell-characterization, and personalized-therapy directions do not establish an operational clinical platform, diagnosis, treatment, cure, safety, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
• Treat Johnson’s October 2026 female nighttime-erection measurement announcement as an attributed N=1 program-extension claim. The male physiology direction is real (Princeton III/IV consensus: ED onset precedes coronary events by 2–5 years), and female REM-linked genital engorgement is documented (Karacan et al. 1970; Fisher et al. 1983, Archives of Sexual Behavior, 10.1007/BF01541556 — cyclic engorgement in 95% of REM periods in 10 women), but the female evidence base is two small studies of vaginal blood flow with no outcome linkage, the device prices ($275 consumer vs. $15,723.68 lab) and 1,900-biomarker figures are program claims, and no published study validates female at-home erection scoring as a health-risk tool—not a monitoring recommendation for readers.https://x.com/bryan_johnson/status/2108705788986634435
• Treat the July 2026 operational Kate Tolo baseline as an N=1 measurement program. The 100-day, 14-million-data-point plan with 100+ daily tasks, 50+ devices, and a 12-person team is not completed evidence, a representative female-health protocol, or reader guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
• Treat Johnson’s August 2026 claim that Kate Tolo’s protocol was built in 90 days and is “better” than his five-year build as an operational comparison only. No quality criteria, comparative measurements, outcomes, or external validation were published.raw/articles/bryan-johnson/x-twitter-daily-2026-08-05.md
• Treat Johnson’s August 2026 47-tube, 250 mL blood draw as a scale and methods update. The post names single-cell immune sequencing and broad measurement domains but publishes no assay list, results, diagnosis, clinical interpretation, or evidence that collection volume improves outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-08-13.md
• Treat Johnson’s August 2026 interval-training post as an attributed exercise claim, not a prescription. The 4×4 shape (3 sessions/week, 4 minutes at 90–95% effort with 3 easy minutes, 8 weeks) is the Helgerud et al. 2007 protocol (+7.2% VO2max), and the “11% lower all-cause mortality” figure compresses per-MET fitness associations (Kodama et al. 2009: 13% lower all-cause mortality per MET, RR 0.87)—no trial has measured mortality from eight weeks of intervals, and the post names no study.https://x.com/bryan_johnson/status/2092230490581574033
• Treat Johnson’s August 2026 LDL post as an attributed cholesterol claim. The “49 trials, 312,175 people, ~23% fewer major vascular events per 39 mg/dL” figure matches Sabatine et al. 2016 (JAMA; RR 0.77 per 1 mmol/L), and the “13–14% over six months” diet figure matches the Jenkins et al. 2011 portfolio-diet RCT (−13.1% to −13.8% LDL from viscous fiber, nuts, plant protein, and plant sterols)—but the post names neither study, and trial-population relative effects are not individual guarantees or a lab-interpretation directive.https://x.com/bryan_johnson/status/2092597711543632216
• Treat Johnson’s August 2026 NTE-by-age decline tables as an attributed normative-data claim. The age-related decline is documented (Karacan et al. 1975 normative NPT series; Schiavi et al. 1988; Horita & Kumamoto 1989: 189.6 min at age 20 declining to ~62 min at 70, nearly matching his age-20 anchor), but the post names no study, its intermediate bins match no single published cohort, and the repeated “2x risk in 4 years” outruns meta-analytic averages—not a validated risk prediction or monitoring recommendation.https://x.com/bryan_johnson/status/2093698799172829255
• Treat Johnson’s September 2026 GLP-1 employment post as an attributed research relay. The underlying study is real (NBER w35387, Diamond: employment among baseline non-employed women rose 13.2 points overall and 26.9 points after six-plus quarters in the Understanding America Study), but Johnson’s “20–25 percentage point increase … over 2 to 3 yrs” paraphrase loosely brackets the paper’s horizons and stretches the window, and the post names no paper—not individual-outcome evidence or a reason to seek medication.https://x.com/bryan_johnson/status/2100763486850805808
• Treat Johnson’s September 2026 son’s-sperm post as an attributed family measurement and advice list. The population anchor is documented (Levine et al. 2017: sperm concentration among unselected Western men fell 52.4% from 1973–2011), but the “top 1%” and “19x WHO minimum” rankings disclose no reference cohort, and the lifestyle list and parent-testing advice are generic guidance without individualization—not fertility guidance or medical advice.https://x.com/bryan_johnson/status/2098185202585747947
• Treat Johnson’s August 2026 Kernel brain-scan percentile post as an attributed self-report. The regional percentiles (amygdala 95th, putamen 99th, caudate 97th, frontal gray matter 78th “and climbing”), heritability figures, and personality mappings are his own account against an undisclosed normative cohort; the plasticity literature he gestures at (Draganski et al. 2004: transient visual-motion-cortex gray-matter change from juggling; Colcombe et al. 2006: frontal-volume gains from aerobic exercise in older adults) does not validate region-by-region self-interpretation—not a brain-health metric, evidence the protocol grew his frontal cortex, or medical advice.https://x.com/bryan_johnson/status/2094112145357291863
• Treat Johnson’s August 2026 nighttime-erection post as an attributed N=1 biomarker claim. ED does precede and predict cardiovascular events (Vlachopoulos et al. 2011 JACC meta-analysis: RR 1.48 CVD, 1.35 stroke; Krimpen cohort: HR 2.6 only for severely reduced rigidity), but his flat “2x risk in 4 years” outruns the meta-analytic averages, the post names no study, consumer NTE scores are not a validated clinical risk tool, and daily tadalafil 5 mg is a prescription medication requiring clinician oversight—not a reader protocol.https://x.com/bryan_johnson/status/2093061998468903267
• Treat the Baseten biological-age event as public measurement positioning. Its brain, skin, strength, balance, reaction-speed, and mobility domains are not evidence that the tests form a validated or actionable biological-age score.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
• Treat the August 2026 meibomian-gland post as an attributed N=1 diagnosis-and-intervention account. Johnson reports advanced MGD with gland dropout, a four-therapy stack (IPL, radiofrequency, intraductal probing, 630nm red light), and a self-reported 30% gland-function improvement; his own post says the probing science is unsettled and the therapies cannot be separated. It is not a validated eye-care protocol or reader guidance.https://x.com/bryan_johnson/status/2089822905891000605
• Preserve medical-caution framing: this page summarizes Johnson/Blueprint practice, not personal treatment advice.concepts/biomarker-driven-longevity-protocols.md